Advertisement

Research Article Free access | 10.1172/JCI108344

Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency.

R P Agarwal, G W Crabtree, R E Parks Jr, J A Nelson, R Keightley, R Parkman, F S Rosen, R C Stern, and S H Polmar

Find articles by Agarwal, R. in: JCI | PubMed | Google Scholar

Find articles by Crabtree, G. in: JCI | PubMed | Google Scholar

Find articles by Parks, R. in: JCI | PubMed | Google Scholar

Find articles by Nelson, J. in: JCI | PubMed | Google Scholar

Find articles by Keightley, R. in: JCI | PubMed | Google Scholar

Find articles by Parkman, R. in: JCI | PubMed | Google Scholar

Find articles by Rosen, F. in: JCI | PubMed | Google Scholar

Find articles by Stern, R. in: JCI | PubMed | Google Scholar

Find articles by Polmar, S. in: JCI | PubMed | Google Scholar

Published April 1, 1976 - More info

Published in Volume 57, Issue 4 on April 1, 1976
J Clin Invest. 1976;57(4):1025–1035. https://doi.org/10.1172/JCI108344.
© 1976 The American Society for Clinical Investigation
Published April 1, 1976 - Version history
View PDF
Abstract

Deficiency of erythrocytic and lymphocytic adenosine deaminase (ADA) occurs in some patients with severe combined immunodeficiency disease (SCID). SCID with ADA deficiency is inherited as an autosomal recessive trait. ADA is markedly reduced or undetectable in affected patients (homozygotes), and approximately one-half normal levels are found in individuals heterozygous for ADA deficiency. The metabolism of purine nucleosides was studied in erythrocytes from normal individuals, four ADA-deficiency patients, and two heterozygous individuals. ADA deficiency in intake erythrocytes was confirmed by a very sensitive ammonia-liberation technique. Erythrocytic ADA activity in three heterozygous individuals (0.07,0.08, and 0.14 mumolar units/ml of packed cells) was between that of the four normal controls (0.20-0.37 mumol/ml) and the ADA-deficient patients (no activity). In vitro, adenosine was incorporated principally into IMP in the heterozygous and normal individuals but into the adenosine nucleotides in the ADa-deficient patients. Coformycin (3-beta-D-ribofuranosyl-6,7,8-trihydroimidazo[4,5-4] [1,3] diazepin-8 (R)-ol), a potent inhibitor of ADA, made possible incorporation of adenosine nucleotides in the ADA-deficient patients...

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (April 1, 1976): No description
Advertisement
Advertisement